SIJIE LU to HLA-A2 Antigen
This is a "connection" page, showing publications SIJIE LU has written about HLA-A2 Antigen.
Connection Strength
1.254
-
Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia. Cytotherapy. 2021 09; 23(9):793-798.
Score: 0.716
-
A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2. Front Immunol. 2018; 9:3153.
Score: 0.151
-
Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. Clin Cancer Res. 2018 07 15; 24(14):3386-3396.
Score: 0.143
-
A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res. 2013 Jan 01; 19(1):247-57.
Score: 0.098
-
An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood. 2011 Apr 21; 117(16):4262-72.
Score: 0.087
-
Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol. 2012 Dec 01; 189(11):5476-84.
Score: 0.025
-
PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One. 2010 Jul 26; 5(7):e11770.
Score: 0.021
-
Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003 Mar; 111(5):639-47.
Score: 0.013